Table 4. mRNA-based vaccines using Lipid nanoparticles (LNPs) for the delivery of cargo.
| Vaccine | Developer | Trial phase |
| ARCoV | Walvax Biotechnology Co., Ltd.; Abogen Biosciences Co. Ltd.; Yuxi Walvax Biotechnology Co., Ltd. | Phase 3 |
| CVnCoV | CureVac; GSK | Phase 2b/3 |
| DS-5670a | Daiichi Sankyo Co., Ltd. | Phase 1/2 |
| MRT5500 | Sanofi, Translate Bio | Phase 1/2 |
| LUNAR-COV19 (ARCT-021) | Arcturus/Duke-NUS/Catalent | Phase 1/2 |
| LNP-nCoVsaRNA | Imperial College | Phase 1/2 |
| (Not named yet) | Shanghai Municipal Science and Technology Commission; Stemirna Therapeutics | Phase 1 |
| (Not named yet) | Gritstone Oncology, Inc.; National Institute of Allergic and Infectious diseases (NIAID) | Phase 1 |
| PTX-COVID19-B | Providence Therapeutics; Canadian government | Phase 1 |
| ChulaCov19 | Chulalongkorn University | Phase 1 |
| D614G variant LNP Encapsulated RNA (Bancovid, Banagavax) | Globe Biotech Ltd | Pre-clinical |
| LNP-encapsulated mRNA encoding S | Max-Planck-Institute of Colloids and Interfaces | Pre-clinical |
| Comirnaty (BNT162b2) | Pfizer, BioNTech; Fosun Pharma | Authorized or approved |
| Moderna COVID-19 Vaccine (mRNA-1273) | Moderna, Biomedical Advanced Research and Development Authority (BARDA), National Institute of Allergic and Infectious diseases (NIAID) | Authorized or approved |
Source: World Health Organization [116].